Purchase this article with an account.
audrey chia; The aim of this study was to evaluate the clinical outcome of children treated with atropine 0.01% in a clinical setting. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3404.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The Atropine for treatment of myopia study (ATOM2) suggests that atropine 0.01% can slow myopia progression in young children. This is a review of patients started clinically on the medication, with the aim of assessing its efficacy in a clinical setting.
A retrospective review/audit was done on myopic children started on atropine 0.01% in paediatric eye clinic between Oct 2013 and Dec 2014. Demographic data, cycloplegic refraction and axial length measures were collected at 6 monthly intervals for up to 2 years.
433 children who were started on medication and the 324 who had 1 year follow-up; and 281 with 2 year follow-up were included in this audit. The mean age of children was 8.9 +/- 1.9 years; with the peak age being between 8-9 years (Figure 1). 43% were male, and 88% were of Chinese ethnicity. The average age when children had started glasses was 6.5 +/- 1.6 years. The mean baseline myopia was -4.94 /- 1.91D, and axial length was 25.11 +/-1.20mm. In children with 1 year follow-up, the mean change in spherical equivalent (SE) was 0.31 +/- 0.39D and 0.60 +/- 0.57D at 6 months and 1 year, respectively. Change in axial length (AL) at 1 year was 0.30 +/- 0.22mm. 281 were still being follow-up at 2 years. Of this, 253 were still using atropine 0.01% daily with the mean change in SE at 2 years being 0.87 +/- 0.53D. .
Use of atropine 0.01% in this clinical setting suggest similar trend of slowing myopia progression as in the randomized clinital trial.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only